Description
CC Super TD-4289 Blood Glucose Monitoring System
Built for Precision. Trusted for Everyday Use.
The CC Super TD-4289 is a professional-grade blood glucose monitoring system that blends speed, accuracy, and ease of use—making it ideal for both home users and healthcare providers.
At its core, the TD-4289 uses GDH-FAD biosensor technology, eliminating interference from common sugars like maltose, galactose, and xylose. This ensures that your readings remain accurate even in complex biological conditions.
🩺 Product Features and Benefits:
-
📈 Advanced Measurement Technology:
Built with GDH-FAD enzyme biosensors, offering lab-level accuracy without the risk of false results from external substances. -
🧠 Smart Data Management:
Stores up to 300 readings, complete with time-stamps and auto-calculates averages for 7, 14, 30, 60, and 90-day periods—empowering users to monitor trends over time. -
🛡️ Safety Alerts:
Features built-in hypoglycemia, hyperglycemia, and ketone warnings, helping you act quickly on abnormal readings. -
🩸 Hematocrit Compatibility:
Operates within a 30–55% HCT range, making it suitable for a wide variety of patients, including those with mild anemia or elevated red blood cell counts. -
🔁 No Coding Needed:
Strips come with auto-calibration circuitry, reducing errors and simplifying testing. -
📟 Unit Flexibility:
Readings can be displayed in mg/dL or mmol/L, depending on user preference or clinical requirements. -
⏰ Testing Support Features:
Set up to 5 daily alarms as reminders for testing—particularly helpful for diabetics who need consistent monitoring. -
🔋 Power Efficiency:
Operates on standard batteries with long usage life, optimized for low power consumption. -
📦 What’s in the Box:
-
CC Super TD-4289 Glucometer
-
10 Free Test Strips
-
Lancing Device & Lancets
-
User Manual
-
Carrying Case
-
-
🌍 Country Support & Warranty:
Comes with a lifetime warranty and after-sales support in Pakistan, making it a dependable long-term solution for glucose monitoring.







Reviews
There are no reviews yet.